Monthly Oral Ibandronate Stacks Up In Japan Trial
This article was originally published in PharmAsia News
Chugai and partner Taisho have released new data from a Phase III Japanese trial with a once-monthly oral formulation of ibandronate for osteoporosis that has confirmed non-inferiority to the injected product and forms the basis of a recent approval filing.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.